Skip to main content
OpenTrials
Completed

NCT Number: NCT00481741

Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions

We seek to determine if the use of the SafeSeal(TM) topical hemostasis patch is associated with reductions in time to hemostasis and time to ambulation compared to standard manual compression after arterial sheath removal following percutaneous coronary and peripheral intervention. We further seek to assess the safety of the SafeSeal patch compared to manual compression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Rochester Medical Center

Rochester, New York, 14642, United States

About this study

A variety of topical hemostasis pads containing procoagulant materials are currently available to accelerate hemostasis after removal of the arterial introducer sheath following coronary and peripheral arterial angioplasty procedures. The effectiveness and safety of these pads, however, remains poorly understood. A total of 150 patients undergoing coronary or peripheral vascular angioplasty through a 6 French arterial sheath will be randomized to sheath removal using manual compression alone or manual compression combined with use of the SafeSeal(TM) hemostasis patch. Sheaths will be removed at an activated clotting time (ACT) of <250 seconds, and patients will be kept at bedrest for 2 hours after hemostasis is achieved. The primary endpoint will be time to hemostasis. Secondary endpoints witll include time to ambulation and frequency of bleeding complications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient ≥ 18 years old
  • Coronary or peripheral vascular intervention
  • 6 French arterial sheath used
  • Overnight hospitalization following procedure

Exclusion criteria

  • Hematoma or persistent bleeding around the vascular sheath
  • Previous AV fistula or pseudoaneurysm in the ipsilateral femoral artery
  • History of bleeding diathesis or coagulopathy
  • Hemoglobin level < 9 g/dl
  • Inability to ambulate at baseline
  • Known allergy to any of the materials used in the SafeSeal
  • Female patients known to be pregnant or lactating
  • Evidence of ongoing systemic or cutaneous infection
  • Uncontrolled blood pressure following PCI (systolic blood pressure > 180 or diastolic blood pressure >110)
  • Current enrolment in another ongoing investigational drug/device trial.

Treatment and study plan

SafeSeal(TM) Hemostasis Patch

Device

Primary outcomes

  1. Time to achieve hemostasis of femoral artery after arterial sheath removal

    Time frame: immediate

Secondary outcomes

  1. vascular access-related bleeding complications

    Time frame: prior to hospital discharge

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

  • MEDRAD, Inc.

Registry information

Official study title

A Prospective Randomized Controlled Efficacy and Safety Trial of the SafeSeal Hemostasis Patch Compared to Manual Compression for Achieving Vascular Hemostasis Following Percutaneous Coronary and Peripheral Intervention.

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Jun 4, 2007
Registry last updated
Jul 31, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.